BeOne Medicines Statistics
Total Valuation
BeOne Medicines has a market cap or net worth of $30.74 billion. The enterprise value is $29.22 billion.
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BeOne Medicines has 127.43 million shares outstanding. The number of shares has increased by 1.47% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 127.43M |
| Shares Change (YoY) | +1.47% |
| Shares Change (QoQ) | +4.62% |
| Owned by Insiders (%) | 4.27% |
| Owned by Institutions (%) | 44.88% |
| Float | 75.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 100.00 |
| PS Ratio | 6.41 |
| Forward PS | 3.45 |
| PB Ratio | 7.80 |
| P/TBV Ratio | 8.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 144.96 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.96 |
| Quick Ratio | 1.64 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.99 |
Financial Efficiency
Return on equity (ROE) is -11.44% and return on invested capital (ROIC) is -4.16%.
| Return on Equity (ROE) | -11.44% |
| Return on Assets (ROA) | -3.22% |
| Return on Invested Capital (ROIC) | -4.16% |
| Return on Capital Employed (ROCE) | -7.69% |
| Revenue Per Employee | $379,624 |
| Profits Per Employee | -$35,670 |
| Employee Count | 11,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.35 |
Taxes
In the past 12 months, BeOne Medicines has paid $123.69 million in taxes.
| Income Tax | 123.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.71% in the last 52 weeks. The beta is 0.30, so BeOne Medicines's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +64.71% |
| 50-Day Moving Average | 247.16 |
| 200-Day Moving Average | 225.68 |
| Relative Strength Index (RSI) | 42.52 |
| Average Volume (20 Days) | 360,820 |
Short Selling Information
The latest short interest is 1.92 million, so 1.51% of the outstanding shares have been sold short.
| Short Interest | 1.92M |
| Short Previous Month | 2.03M |
| Short % of Shares Out | 1.51% |
| Short % of Float | 2.54% |
| Short Ratio (days to cover) | 5.91 |
Income Statement
In the last 12 months, BeOne Medicines had revenue of $4.18 billion and -$392.37 million in losses. Loss per share was -$3.70.
| Revenue | 4.18B |
| Gross Profit | 3.54B |
| Operating Income | -296.56M |
| Pretax Income | n/a |
| Net Income | -392.37M |
| EBITDA | -122.01M |
| EBIT | -296.56M |
| Loss Per Share | -$3.70 |
Full Income StatementBalance Sheet
The company has $2.52 billion in cash and $996.83 million in debt, giving a net cash position of $1.52 billion or $11.92 per share.
| Cash & Cash Equivalents | 2.52B |
| Total Debt | 996.83M |
| Net Cash | 1.52B |
| Net Cash Per Share | $11.92 |
| Equity (Book Value) | 3.50B |
| Book Value Per Share | 32.42 |
| Working Capital | 1.91B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $212.02 million and capital expenditures -$392.49 million, giving a free cash flow of -$180.47 million.
| Operating Cash Flow | 212.02M |
| Capital Expenditures | -392.49M |
| Free Cash Flow | -180.47M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
Gross margin is 84.81%, with operating and profit margins of -7.10% and -9.40%.
| Gross Margin | 84.81% |
| Operating Margin | -7.10% |
| Pretax Margin | -6.43% |
| Profit Margin | -9.40% |
| EBITDA Margin | -2.92% |
| EBIT Margin | -7.10% |
| FCF Margin | n/a |
Dividends & Yields
BeOne Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.47% |
| Shareholder Yield | -1.47% |
| Earnings Yield | -1.28% |
| FCF Yield | -0.59% |
Analyst Forecast
The average price target for BeOne Medicines is $325.56, which is 34.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $325.56 |
| Price Target Difference | 34.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 75.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BeOne Medicines has an Altman Z-Score of 4.11 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.11 |
| Piotroski F-Score | 5 |